NCT04478461 is a Phase 1 clinical trial of PD-1 monoclonal antibody in Advanced Solid Tumor, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd..

Who is sponsoring NCT04478461?

NCT04478461 is sponsored by Mabwell (Shanghai) Bioscience Co., Ltd..

What drugs are being tested in NCT04478461?

Interventions in NCT04478461: PD-1 monoclonal antibody.

What condition does NCT04478461 study?

NCT04478461 studies Advanced Solid Tumor.

Is NCT04478461 still recruiting?

NCT04478461 is currently status unknown. Last updated 13 November 2020.

Last reviewed 2020-11-13 · How we verify

NCT04478461

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Status unknown Phase 1 Last updated 13 November 2020

What this trial tests

Phase 1 trial testing PD-1 monoclonal antibody in Advanced Solid Tumor in 21 participants. Status unknown.

Timeline

3 September 2020

Primary endpoint
5 January 2023

2 February 2023

Quick facts

Lead sponsor	Mabwell (Shanghai) Bioscience Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	3 September 2020
Primary completion	5 January 2023
Estimated completion	2 February 2023
Sites	1 location across China

Drugs / interventions tested

PD-1 monoclonal antibody — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase Ia, single-center, open label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor efficacy of MW11 (a recombinant humanized anti-PD-1 monoclonal antibody) for injection in patients with advanced solid tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors.
Blanco E, Chocarro L, Fernández-Rubio L, Bocanegra A, et al · · 2023 · cited 12× · PMID 36768997 · DOI 10.3390/ijms24032676

Verify or expand the search:

Other trials of PD-1 monoclonal antibody

Trials testing the same drug.

NCT06908031 — SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer · Phase 2 · recruiting
NCT06364787 — Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-li · Phase 1 · not yet recruiting
NCT06364800 — Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocel · EARLY_PHASE1 · not yet recruiting
NCT06311929 — Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma · Phase 4 · recruiting
NCT05821192 — Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. · NA · unknown

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Mabwell (Shanghai) Bioscience Co., Ltd. trials

Trials by the same sponsor.

NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07314723 — 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer · Phase 2 · recruiting
NCT06926998 — 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors · Phase 1, PHASE2 · not yet recruiting
NCT06804590 — A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis · Phase 3 · recruiting
NCT06692166 — A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Ca · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04478461 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mabwell (Shanghai) Bioscience Co., Ltd.
Last refreshed: 13 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04478461.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing